82 percent of Patients Achieved a Complete Remission when Lymphodepletion Regimen Included an anti-CD52 Monoclonal Antibody (mAb) Safety Profile of UCART19 Appears Manageable with No Evidence of Moderate or Severe Graft-vs-Host Disease (GvHD) and No Severe Neurotoxicities Analysis Suggests that an

Preclinical Data Supports Advancement of ALLO-715 into Phase 1 in Multiple Myeloma ALLO-715 Investigational New Drug Application and Initiation of a Phase 1 Trial Planned for 2019 SOUTH SAN FRANCISCO, Calif. , Dec. 03, 2018 (GLOBE NEWSWIRE) --   Allogene Therapeutics, Inc.

SOUTH SAN FRANCISCO, Calif. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at two investor

Data Provide Insights in Preparation for Investigational New Drug (IND) Submissions Planned in 2019 for ALLO-501 (anti-CD19) in Non-Hodgkin Lymphoma and ALLO-715 (anti-BCMA) in Multiple Myeloma SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 1, 2018-- Allogene Therapeutics, Inc.

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 15, 2018-- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced the closing of its previously announced initial public

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T(AlloCAR T™) therapies for cancer, today announced the pricing of its initial public offering of 18,000,000 shares of its common stock at